KR20180122028A - 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 - Google Patents
의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 Download PDFInfo
- Publication number
- KR20180122028A KR20180122028A KR1020187031264A KR20187031264A KR20180122028A KR 20180122028 A KR20180122028 A KR 20180122028A KR 1020187031264 A KR1020187031264 A KR 1020187031264A KR 20187031264 A KR20187031264 A KR 20187031264A KR 20180122028 A KR20180122028 A KR 20180122028A
- Authority
- KR
- South Korea
- Prior art keywords
- charom
- compound
- group
- arom
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1150651 | 2011-01-27 | ||
| FR1150651A FR2970967B1 (fr) | 2011-01-27 | 2011-01-27 | Derives de type azaindazole ou diazaindazole comme medicament |
| PCT/EP2012/051283 WO2012101239A1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137022330A Division KR101923751B1 (ko) | 2011-01-27 | 2012-01-27 | 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180122028A true KR20180122028A (ko) | 2018-11-09 |
Family
ID=44318089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187031264A Ceased KR20180122028A (ko) | 2011-01-27 | 2012-01-27 | 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 |
| KR1020137022330A Expired - Fee Related KR101923751B1 (ko) | 2011-01-27 | 2012-01-27 | 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137022330A Expired - Fee Related KR101923751B1 (ko) | 2011-01-27 | 2012-01-27 | 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20130172360A1 (enExample) |
| EP (1) | EP2668184B1 (enExample) |
| JP (1) | JP5931926B2 (enExample) |
| KR (2) | KR20180122028A (enExample) |
| CN (1) | CN103339129B (enExample) |
| AR (1) | AR084935A1 (enExample) |
| AU (1) | AU2012210467B2 (enExample) |
| BR (1) | BR112013018852B1 (enExample) |
| CA (1) | CA2823824C (enExample) |
| CY (1) | CY1120088T1 (enExample) |
| DK (1) | DK2668184T3 (enExample) |
| ES (1) | ES2661695T3 (enExample) |
| FR (1) | FR2970967B1 (enExample) |
| HR (1) | HRP20180524T1 (enExample) |
| HU (1) | HUE037153T2 (enExample) |
| IL (2) | IL227496B (enExample) |
| LT (1) | LT2668184T (enExample) |
| MA (1) | MA34903B1 (enExample) |
| MX (1) | MX356411B (enExample) |
| MY (1) | MY180666A (enExample) |
| PL (1) | PL2668184T3 (enExample) |
| PT (1) | PT2668184T (enExample) |
| RS (1) | RS57101B1 (enExample) |
| RU (1) | RU2600976C2 (enExample) |
| SI (1) | SI2668184T1 (enExample) |
| TN (1) | TN2013000293A1 (enExample) |
| TR (1) | TR201802944T4 (enExample) |
| TW (1) | TWI546303B (enExample) |
| UA (1) | UA109698C2 (enExample) |
| WO (1) | WO2012101239A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR102469849B1 (ko) | 2013-04-19 | 2022-11-23 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| US10211205B2 (en) * | 2016-04-27 | 2019-02-19 | International Business Machines Corporation | Field effect transistor structure for reducing contact resistance |
| CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7322140B6 (ja) * | 2018-05-02 | 2024-02-21 | ジェイダブリュ ファーマシューティカル コーポレーション | 新規なヘテロサイクル誘導体 |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| JP2023509421A (ja) * | 2019-12-31 | 2023-03-08 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115916771B (zh) * | 2020-04-02 | 2025-04-01 | 浙江华海药业股份有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| CN116745268A (zh) * | 2020-11-20 | 2023-09-12 | 2692372安大略公司 | 苯磺酰胺衍生物及其用途 |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE242245T1 (de) * | 1997-03-19 | 2003-06-15 | Basf Ag | Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren |
| EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
| CZ20024176A3 (cs) | 2000-06-22 | 2004-01-14 | Pfizer Inc. | Způsob výroby pyrazolopyrimidinonů |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| MX2008002385A (es) * | 2005-08-25 | 2008-03-18 | Hoffmann La Roche | Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos. |
| EP2044068A4 (en) | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs |
| DK2120932T3 (da) | 2006-12-20 | 2014-10-13 | Nerviano Medical Sciences Srl | Indazolderivater som kinasehæmmere til behandling af kræft |
| SG183049A1 (en) | 2007-07-20 | 2012-08-30 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| US8354399B2 (en) | 2008-12-18 | 2013-01-15 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
-
2011
- 2011-01-27 FR FR1150651A patent/FR2970967B1/fr active Active
-
2012
- 2012-01-20 TW TW101102531A patent/TWI546303B/zh active
- 2012-01-27 TR TR2018/02944T patent/TR201802944T4/tr unknown
- 2012-01-27 AR ARP120100272A patent/AR084935A1/es active IP Right Grant
- 2012-01-27 DK DK12701884.4T patent/DK2668184T3/en active
- 2012-01-27 RU RU2013138624/04A patent/RU2600976C2/ru active
- 2012-01-27 HR HRP20180524TT patent/HRP20180524T1/hr unknown
- 2012-01-27 PL PL12701884T patent/PL2668184T3/pl unknown
- 2012-01-27 KR KR1020187031264A patent/KR20180122028A/ko not_active Ceased
- 2012-01-27 JP JP2013550886A patent/JP5931926B2/ja active Active
- 2012-01-27 SI SI201231273T patent/SI2668184T1/en unknown
- 2012-01-27 BR BR112013018852-9A patent/BR112013018852B1/pt not_active IP Right Cessation
- 2012-01-27 EP EP12701884.4A patent/EP2668184B1/en active Active
- 2012-01-27 UA UAA201310425A patent/UA109698C2/ru unknown
- 2012-01-27 CN CN201280006671.8A patent/CN103339129B/zh active Active
- 2012-01-27 MY MYPI2013002799A patent/MY180666A/en unknown
- 2012-01-27 PT PT127018844T patent/PT2668184T/pt unknown
- 2012-01-27 CA CA2823824A patent/CA2823824C/en active Active
- 2012-01-27 WO PCT/EP2012/051283 patent/WO2012101239A1/en not_active Ceased
- 2012-01-27 ES ES12701884.4T patent/ES2661695T3/es active Active
- 2012-01-27 HU HUE12701884A patent/HUE037153T2/hu unknown
- 2012-01-27 RS RS20180418A patent/RS57101B1/sr unknown
- 2012-01-27 MX MX2013008673A patent/MX356411B/es active IP Right Grant
- 2012-01-27 MA MA36177A patent/MA34903B1/fr unknown
- 2012-01-27 KR KR1020137022330A patent/KR101923751B1/ko not_active Expired - Fee Related
- 2012-01-27 US US13/823,658 patent/US20130172360A1/en not_active Abandoned
- 2012-01-27 AU AU2012210467A patent/AU2012210467B2/en not_active Ceased
- 2012-01-27 LT LTEP12701884.4T patent/LT2668184T/lt unknown
- 2012-11-27 US US13/686,334 patent/US8883821B2/en active Active
-
2013
- 2013-07-11 TN TNP2013000293A patent/TN2013000293A1/fr unknown
- 2013-07-16 IL IL227496A patent/IL227496B/en active IP Right Grant
-
2018
- 2018-02-26 IL IL257748A patent/IL257748B/en active IP Right Grant
- 2018-03-26 CY CY20181100338T patent/CY1120088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101923751B1 (ko) | 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체 | |
| JP6732855B2 (ja) | 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体 | |
| EP2877176B1 (en) | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | |
| CN107074787A (zh) | 赖氨酸特异性脱甲基酶‑1的抑制剂 | |
| CN103228656B (zh) | 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物 | |
| HK1186737B (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| OA16493A (en) | Derivatives of azaindazole or diazaindazole type as medicament. | |
| NZ614432B2 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| HK1207302B (en) | Derivatives of azaindazole or diazaindazole type for treating pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20181029 Application number text: 1020137022330 Filing date: 20130823 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181203 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20190801 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20181203 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |